Aspen Neuroscience Inc(ASPE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
ASPE
New Aspen Neuroscience Inc
$14.89
-0.11 ▼ -0.73%
Oct 30 at 5:15 PM ET (Korea 10/31 06:15)$14.89
+0.00 +0.00%
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 29.1M | Perf Week | - |
| Market Cap | 0.43B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | - |
| Enterprise Value | 0.71B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | - |
| Book/sh | -8.63 | P/C | 5.98 | EPS past 3/5Y | - | ROE | - | 52W High | - | Perf Year | - |
| Cash/sh | 2.49 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | - | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.56 | EPS Q/Q | - | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.56 | Sales Q/Q | - | SMA20 | 0% ($14.89) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | 0% ($14.89) | Rel Volume | - | Prev Close | $15 |
| Employees | 117 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 0% ($14.89) | Avg Volume(3M) | - | Price | $14.89 |
| IPO | 2026/10/30 | Option/Short | No/No | Trades | 3675 | Volume | 1,322,744 | Change | -0.73% |
Company
ASPEAspen Neuroscience Inc | NASD | Biotechnology Quote
Over the past 1 year, roughly in the middle
52W Range-
Volume 1,322,744
C
Overall · average, with some caution
We judged 3 of the 8 questions below. All are average.
No data for growth, valuation, earnings, outlook, dividends, or not applicable.
Has it trended upward long-term? B
Long-term returns are roughly flat
Tap to view numbers
How about dividends?
No dividend
There is no profit to distribute yet.
Who owns it? B
Ownership is about average
Shareholder Composition Guide
Tap to view numbers
Peer comparison Biotechnology
It ranks #229 of 597 in the industry
Based on market cap of $433M.
EPRX#225 Eupraxia Pharmaceuticals Inc $444M PER - 
CRMD#226 CorMedix Inc $444M PER 2.7 
BLSM#227 BlossomHill Therapeutics Inc $437M PER - 
PRTA#228 Prothena Corp Plc $435M PER - ASPE#229 Aspen Neuroscience Inc $433M PER - Reads on this stock 1 posts
FAQ
Briefs · earnings · signals, first Telegram · KakaoTalk channels
